Type 2 11 beta-hydroxysteroid dehydrogenase in foetal and adult life

被引:91
|
作者
Stewart, PM [1 ]
Whorwood, CB [1 ]
Mason, JI [1 ]
机构
[1] UNIV TEXAS,SW MED CTR,GREEN CTR REPROD BIOL SCI,DALLAS,TX 75235
关键词
D O I
10.1016/0960-0760(95)00195-6
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Two isoforms of 11 beta-hydroxysteroid dehydrogenase (11 beta-HSD) catalyse the interconversion of active cortisol to inactive cortisone; 11 beta-HSD1 is a low affinity, NADP(H)-dependent dehydrogenase/oxo-reductase, and 11 beta-HSD2, a high affinity, NAD-dependent dehydrogenase. Because of the importance of 11 beta-HSD in regulating corticosteroid hormone action, we have analysed the distribution of the 11 beta-HSD isoforms in human adult and foetal tissues (including placenta), and, in addition have performed a series of substrate specificity studies on the novel, kidney 11 beta-HSD2 isoform. Using an RT-PCR approach, we failed to detect 11 beta-HSD1 mRNA in any human mid-gestational foetal tissues. In contrast 11 beta-HSD2 mRNA was present in foetal lung, adrenal, colon and kidney. In adult tissues 11 beta-HSD2 gene expression was confined to the mineralocorticoid target tissues, kidney and colon, whilst 11 beta-HSD1 was expressed predominantly in glucocorticoid target tissues, liver, lung, pituitary and cerebellum. In human kidney homogenates, 11-hydroxylated progesterone derivatives, glycyrrhetinic acid, corticosterone and the ''end products'' cortisone and 11-dehydrocorticosterone were potent inhibitors of the NAD-dependent conversion of cortisol to cortisone. Finally high levels of 11 beta-HSD2 mRNA and activity were observed in term placentae, which correlated positively with foetal weight. The tissue-specific distribution of the 11 beta-HSD isoforms is in keeping with their differential roles, 11 beta-HSD1 regulating glucocorticoid hormone action and 11 beta-HSD2 mineralocorticoid hormone action. The correlation of 11 beta-HSD2 activity in the placenta with foetal weight suggests, in addition, a crucial role for this enzyme in foetal development, possibly in mediating ontogeny of the foetal hypothalamo-pituitary-adrenal axis.
引用
收藏
页码:465 / 471
页数:7
相关论文
共 50 条
  • [1] 11 beta-Hydroxysteroid dehydrogenase type 1 and bone
    Cooper, M. S.
    OSTEOLOGIE, 2016, 25 (04) : 256 - 261
  • [3] Adrenal 11 beta-hydroxysteroid dehydrogenase
    Shimojo, M
    Condon, J
    Whorwood, CB
    Stewart, PM
    ENDOCRINE RESEARCH, 1996, 22 (04) : 771 - 780
  • [4] 11 beta-hydroxysteroid dehydrogenase type 1 in obese children
    Wiegand, S.
    Richardt, A.
    Remer, T.
    Wudy, S. A.
    Tomlinson, J. W.
    Grueters, A.
    PM, Stewart
    Strasburger, C. J.
    Quinkler, M.
    EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2007, 115 : S32 - S32
  • [5] Furosemide (F) inhibits 11 beta-hydroxysteroid dehydrogenase type 2 (11 beta-OHSD2).
    Vogt, B
    Escher, G
    Frey, BM
    Frey, FJ
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 1997, 8 : A1896 - A1896
  • [6] The 11 beta-hydroxysteroid dehydrogenase system, a determinant of glucocorticoid and mineralocorticoid action - Role of type-1 11 beta-hydroxysteroid dehydrogenase in detoxification processes
    Maser, E
    Oppermann, UCT
    EUROPEAN JOURNAL OF BIOCHEMISTRY, 1997, 249 (02): : 365 - 369
  • [7] Oxoreductase and dehydrogenase activities of the human and rat 11 beta-hydroxysteroid dehydrogenase type 2 enzyme
    Li, KXZ
    Obeyesekere, VR
    Krozowski, ZS
    Ferrari, P
    ENDOCRINOLOGY, 1997, 138 (07) : 2948 - 2952
  • [8] 11 beta-hydroxysteroid dehydrogenase in the Dahl rat
    FrancoSaenz, R
    Tokita, Y
    Latif, S
    Morris, DJ
    AMERICAN JOURNAL OF HYPERTENSION, 1997, 10 (09) : 1004 - 1009
  • [9] 11 beta-Hydroxysteroid dehydrogenase in the rat adrenal
    Shimojo, M
    Whorwood, CB
    Stewart, PM
    JOURNAL OF MOLECULAR ENDOCRINOLOGY, 1996, 17 (02) : 121 - 130
  • [10] Vascular localization of the 11 beta-hydroxysteroid dehydrogenase type II enzyme
    Smith, RE
    Little, PJ
    Maguire, JA
    SteinOakley, AN
    Krozowski, ZS
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 1996, 23 (6-7) : 549 - 551